Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

NIH’s Center for Regenerative Medicine (CRM) will engineer stem cells to create isogenic disease models with induced mutations and/or lineage markers using Horizon Discovery’s GENESIS™ genome editing ...

Horizon Discovery and the Translational Genomics Research Institute (TGen) has announced plans to develop human disease models for use in TGen’s cancer research. A research-collaboration and ...

FARMINGTON, Conn., Nov. 16, 2010 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (Nasdaq:HRZN) announced today the full repayment of a $4 million venture loan made by Horizon to Genesis ...